Paul Tudor Jones sees potential market rally after late October
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced Tuesday that it has issued a statement regarding the final IPAY 2028 guidance for Medicare price negotiations released by the U.S. Centers for Medicare & Medicaid Services. According to Halozyme, the statement includes the company’s long-term projections of U.S. Medicare Part B spending as a percentage of total ENHANZE partner product subcutaneous sales.
The company disclosed that a copy of the statement is available on its corporate website and was attached as Exhibit 99.1 to its current report on Form 8-K filed with the Securities and Exchange Commission.
No additional financial statements or detailed projections were provided in the filing. The information is based on a press release statement included in Halozyme’s SEC filing.
In other recent news, Halozyme Therapeutics has announced its acquisition of Elektrofi for $750 million, with the deal expected to close in the fourth quarter of 2025, pending regulatory review. This acquisition aims to expand Halozyme’s drug delivery technology and includes potential milestone payments contingent on product regulatory approvals. In related developments, H.C. Wainwright raised its price target for Halozyme to $90 while maintaining a Buy rating, reflecting an adjusted model that considers the company’s upfront payment for Elektrofi’s technology. Meanwhile, Leerink Partners increased its price target to $70 from $51, citing the acquisition as a strategic move that could enhance Halozyme’s growth rate, although they maintained an Underperform rating.
Additionally, Citizens JMP reaffirmed its Market Outperform rating and a $91 price target for Halozyme, noting positive implications from recent CMS guidance related to Medicare drug price negotiations. In corporate leadership news, Cortney Caudill has been appointed as the Chief Operating Officer, effective immediately. Caudill has a diverse background with previous roles at Aeglea Biotherapeutics and other prominent companies in the biopharmaceutical industry. These developments reflect ongoing strategic and operational changes at Halozyme, which are being closely monitored by analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.